Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VICTOR-6 study.
Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Benedetta Pellegrino(University of Parma), Maria Rosaria Valerio(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Rosalba Rossello(Fondazione Vincenzo Pansadoro), Silvana Saracchini(Centro di Riferimento Oncologico), Enrico Maria Romano De Conciliis(Azienda Sanitaria Locale di Asti), Lucia Stocchi(Ospedale Infermi di Rimini), Anna Maria Vandone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Luca Clivio(Mario Negri Institute for Pharmacological Research), Maria Concetta Cursano(Università Campus Bio-Medico), Luigi Cavanna(University of Pavia), Giovanni Scognamiglio(Ospedale Valduce), Salvatore Russo(Imperial College Healthcare NHS Trust), Virginia Casadei(San Salvatore Hospital), Vittorio Gebbia(La Maddalena), Salvatore Ortu(Associazione Italiana Di Oncologia Medica), D. Toniolo(CTO Hospital), Elisabetta Melegari(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Graziella Pinotti(Medica (Italy))
Cited by 2
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Distance as a Barrier to Cancer Diagnosis and Treatment: Review of the Literature
|The Oncologist|2015|531